Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Adjuvanted quadrivalent flu vacc (SA, inact) inj 0.5ml pfs
1404000H0AAANAN
|
Influenza | Influenza | Immunological Products and Vaccines | 3,090,942 |
|
Influenza vaccine (surface antigen, inact) inj 0.5ml pfs
1404000H0AAAFAF
|
Influenza | Influenza | Immunological Products and Vaccines | 1,371,586 |
|
Adjuvanted trivalent flu vacc (SA, inact) inj 0.5ml pfs
1404000H0AAAMAM
|
Influenza | Influenza | Immunological Products and Vaccines | 613,950 |
|
Quadrivalent Flu/Vac/Split inj 0.5ml pfs
1404000H0BWAAAK
|
Quadrivalent | Influenza | Immunological Products and Vaccines | 573,361 |
|
Flucelvax Tetra vacc inj 0.5ml pre-filled syringes
1404000H0BZAAAF
|
Flucelvax Tetra | Influenza | Immunological Products and Vaccines | 276,794 |
|
Fluad vacc inj 0.5ml pre-filled syringes
1404000H0BXAAAM
|
Fluad | Influenza | Immunological Products and Vaccines | 197,053 |
|
Influvac sub-unit Tetra vacc inj 0.5ml pre-filled syringes
1404000H0BCADAF
|
Influvac Sub-Unit | Influenza | Immunological Products and Vaccines | 172,932 |
|
Typhim Vi 25micrograms/0.5ml vacc inj pre-filled syringes
1404000S0BEAAAD
|
Typhim VI | Typhoid | Immunological Products and Vaccines | 125,400 |
|
Quadrivalent Flu/Vac/Split High-Dose inj 0.7ml pfs
1404000H0BWABAQ
|
Quadrivalent | Influenza | Immunological Products and Vaccines | 116,624 |
|
Pneumovax 23 inj 0.5ml pre-filled syringes
1404000L0BBADAC
|
Pneumovax | Pneumococcal | Immunological Products and Vaccines | 83,780 |
|
Revaxis vacc inj 0.5ml pre-filled syringes
1404000F0BLAAAW
|
Revaxis | Diphtheria | Immunological Products and Vaccines | 73,171 |
|
Avaxim vacc inj 0.5ml pre-filled syringes
140400030BCAAAD
|
Avaxim | Hepatitis A | Immunological Products and Vaccines | 60,901 |
|
Pneumococcal polysaccharide vacc inj 0.5ml vials
1404000L0AAABAB
|
Pneumococcal | Pneumococcal | Immunological Products and Vaccines | 28,194 |
|
Havrix Monodose vacc inj 1ml pre-filled syringes
140400030BBACAC
|
Havrix | Hepatitis A | Immunological Products and Vaccines | 25,026 |
|
Influvac Sub-unit vacc inj 0.5ml pre-filled syringes
1404000H0BCAAAF
|
Influvac Sub-Unit | Influenza | Immunological Products and Vaccines | 18,483 |
|
Fluad Tetra vaccine inj 0.5ml pre-filled syringes
1404000H0CCAAAN
|
Fluad Tetra | Influenza | Immunological Products and Vaccines | 16,992 |
|
Influenza Tetra MYL vacc inj 0.5ml pre-filled syringes
1404000H0BYAAAF
|
Influenza MYL | Influenza | Immunological Products and Vaccines | 16,473 |
|
Engerix B 20micrograms/1ml vacc inj pre-filled syringes
1404000G0BCACAC
|
Engerix B | Hepatitis B | Immunological Products and Vaccines | 10,719 |
|
Havrix Junior Monodose vacc inj 0.5ml pre-filled syringes
140400030BBADAD
|
Havrix | Hepatitis A | Immunological Products and Vaccines | 10,453 |
|
Avaxim Junior vacc inj 0.5ml pre-filled syringes
140400030BCABAD
|
Avaxim | Hepatitis A | Immunological Products and Vaccines | 7,693 |
|
Twinrix Adult vacc inj 1ml pre-filled syringes
140400070BBAAAA
|
Twinrix | Hepatitis A/hepatitis B | Immunological Products and Vaccines | 5,202 |
|
Pneumococcal polysaccharide vacc inj 0.5ml pfs
1404000L0AAACAC
|
Pneumococcal | Pneumococcal | Immunological Products and Vaccines | 3,661 |
|
Engerix B 10micrograms/0.5ml vacc inj pre-filled syringes
1404000G0BCADAI
|
Engerix B | Hepatitis B | Immunological Products and Vaccines | 3,569 |
|
VAQTA Adult vacc inj 1ml pre-filled syringes
140400030BDABAC
|
VAQTA | Hepatitis A | Immunological Products and Vaccines | 2,992 |
|
Supemtek Quadrivalent vaccine (recombinant) inj 0.5ml pfs
1404000H0CEAAAP
|
Supemtek | Influenza | Immunological Products and Vaccines | 2,423 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.